Table 1 Globally approved and marketed antibody-drug conjugates.
Trade name | Name of drug | Research and development organization | Date of first listing | Therapeutic target | Type of cancer |
|---|---|---|---|---|---|
Mylotarg | Gemtuzumab Ozogamicin | Pfizer, American pharmaceutical company | 2000/05/17 (first authorized) 2010/06 (withdrawn from the market) 2017/09/01 (reauthorized) | CD33 | Leukaemia |
Adcetris | Brentuximab Vedotin | SEAGEN/Takeda | 2011/08/19 | CD30 | Hodgkin’s lymphoma, Mesenchymal large cell lymphoma |
Kadcyla | Trastuzumab Emtansine | F. Hoffmann-La Roche Ltd | 2013/02/22 | HER2 | HER2-positive breast cancer |
Besponsa | Inotuzumab Ozogamicin | Pfizer, American pharmaceutical company | 2017/06/28 | CD22 | B-cell acute lymphoblastic leukemia |
Lumoxiti | Moxetumomab Pasudotox | AstraZeneca | 2018/09/13 | CD22 | Capillary leukemia |
Polivy | Polatuzumab Vedotin | F. Hoffmann-La Roche Ltd | 2019/06/10 | CD79b | Diffuse large B-cell lymphoma |
Padcev | Enfortumab Vedotin | SEAGEN/Anstellar | 2019/12/18 | Nectin-4 | Urothelial carcinoma |
Enhertu | Trastuzumab Deruxtecan | Daiichi Sankyo/AstraZeneca | 2019/12/20 | HER2 | HER2-positive breast cancer |
Trodelvy | Sacituzumab Govitecan | Gilead, an American pharmaceutical company | 2020/04/22 | Trop-2 | Triple-negative breast cancer |
Blenrep | Belantamab Mafodotin | GSK | 2020/08/05 (first approved) 2022/11/22 (withdrawn from the market) | BCMA | Multiple myeloma |
Akalux | Cetuximab Saratolacan | Rakuten Medical | 2020/09/25 | EGFR | Head and neck cancer |
Zynlonta | Loncastuximab Tesirine | ADC Therapeutics | 2021/04/23 | CD19 | B-cell lymphoma |
Disitamab Vedotin | Vidicilimumab | Rongchang Bio | 2021/06/08 | HER2 | Gastric cancer |
Tivdak | Tisotumab Vedotin | Genmab/Seagen | 2021/09/20 | TF | Cervix |
Elahere | Mirvetuximab Soravtansine | ImmunoGen/Donghua Pharmaceuticals | 2022/11/14 | FRα | Epithelial ovarian, Fallopian tube, Primary peritoneal cancer |
